The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Anoro Ellipta

GlaxoSmithKline (Ireland) LimitedEU/1/14/898/001-003

Main Information

Trade NameAnoro Ellipta
Active SubstancesVilanterol trifenatate
Umeclidinium bromide
Dosage FormInhalation powder, pre-dispensed
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberEU/1/14/898/001-003

Group Information

ATC CodeR03AL03 vilanterol and umeclidinium bromide


License statusAuthorised
Licence Issued08/05/2014
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back